On 23 August 2017, orphan designation (EU/3/17/1907) was granted by the European Commission to Trimunocor Ltd, United Kingdom, for recombinant fragment of human surfactant protein-D for the prevention of bronchopulmonary dysplasia.

The sponsorship was transferred to Premier Research Group S.L., Spain, in August 2019.

Key facts

Active substance
Recombinant fragment of human surfactant protein-D
Medicine name
Disease / condition
Prevention of bronchopulmonary dysplasia
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Premier Research Group S.L.
Camino De La Zarzuela 19
28023 Madrid
Tel. +34 9103 88900

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating